BioCentury
ARTICLE | Financial News

AnchorDx raises $28M in series B round

November 7, 2017 9:38 PM UTC

Medical technology play AnchorDx Corp. (Guangzhou, China) raised $28 million in a series B round led by 6 Dimensions Capital and Sijia Jianxin Fund. New investors Arch Venture Partners, the WuXi PharmaTech Inc. subsidiary of New WuXi Life Science Ltd. (Shanghai, China) and Guangzhou KingMed Center for Clinical Laboratory Co. Ltd. (Guangzhou, China) also participated, as did existing investor Marathon Venture Partners.

AnchorDx's pipeline includes AnchorAIM, a high throughput screening service to detect mutations in lung cancer, colorectal cancer and solid tumors; AnchorGPS, a diagnostic test in development for lung cancer nodules and colorectal cancer to identify DNA methylation site changes; and AnchorIRIS and AnchorMonarch, which provide targeted DNA methylation high throughput sequencing for patient samples for early stage cancer screening and diagnosis...